Skip to content
Getting Misfolding Proteins to Shape Up episode artwork

Mar 13, 2019 24 min

Getting Misfolding Proteins to Shape Up

from RARECast

Transthyretin is a protein found in the blood. Its name reflects its function, which is to transport thyroxine and retinol. In the case of a number of rare conditions, the protein becomes unstable and misfold, causing it to accumulate as toxic protein deposits in the heart or peripheral nerves. Eidos Therapeutics, a subsidiary of BridgeBio, is developing an experimental small molecule drug that binds and stabilizes transthyretin in the blood. We spoke to Jonathan Fox, chief medical officer of Eidos, about the rare diseases it is targeting, the treatments available today, and how it may change the landscape for these conditions.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Getting Misfolding Proteins to Shape Up

0:00 24:29

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 24 minutes long.

When was this RARECast episode published?

This episode was published on March 13, 2019.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.